Globalization and Regulation in the Biotech World

The Transatlantic Debates over Cancer Genes and Genetically Modified Crops

Bibliographic Data

ID3924824
AuthorsJean-Paul Gaudillière (0009-0008-6984-2667, corresponding author), Jean‐paul Gaudillière
Year2006
Volume21
Issue1
Pages251-272
Publication date2006-01-01
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueOsiris (JOURNAL)
Journal identifiersISSN: 0369-7827 • E-ISSN: 1933-8287
PublisherUniversity of Chicago Press (PUBLISHER • US)
DOI10.1086/507144
OpenAlexW1965045466
LanguageEN
Citations received4
References cited13

Biotechnology has become a major issue in international affairs. This paper follows the scientific and public debates on genetic testing for breast cancer predispositions and genetically modified organisms, which surfaced in France and in the United States during the 1990s. It focuses on the contrasting ways in which intellectual property rights and issues of risks were addressed in both countries. The two case studies suggest that transatlantic tensions about biotechnology are rooted in different forms of regulation. While civic regulation has emerged on both sides of the Atlantic, France remains a privileged terrain for professional regulation under the umbrella of the state, whereas the United States has increasingly relied on industrial regulation

Biology · Environmental ethics · Globalization · Intellectual property · Political economy · Political science · Sociology · Biomedical Ethics and Regulation · Intellectual Property and Patents · Law · Biotechnology

Tools

Open DOISci-Hub